Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Zhongheng Group

    • Home
    • Zhongheng Group
Company Deals

Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01

Fineline Cube Aug 5, 2025

China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng...

Company Deals

Zhongheng Group and Fosun Pharmaceutical Form JV to Boost Overseas Business

Fineline Cube Dec 30, 2024

China-based Zhongheng Group (SHA: 600252) has announced plans to establish a joint venture (JV) with...

Company Deals

Shanghai Fosun Pharmaceutical Partners with State-owned Firms to Boost ASEAN Drug Trade

Fineline Cube Sep 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in...

Recent updates

  • Hengrui’s Rezvilutamide Receives EMA Acceptance for Metastatic Prostate Cancer Treatment
  • AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline
  • BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform
  • CARsgen Therapeutics Secures World’s First Solid Tumor CAR-T Approval with Kylimei for Gastric Cancer
  • Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s Rezvilutamide Receives EMA Acceptance for Metastatic Prostate Cancer Treatment

Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Company Drug

CARsgen Therapeutics Secures World’s First Solid Tumor CAR-T Approval with Kylimei for Gastric Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.